Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow References
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Disclaimer
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Giuliano, F.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Giuliano, F.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


Phosphodiesterase type 5 inhibition in erectile dysfunction: an overview

F. Giuliano1

Department of Urology, Centre Hospitalier Universitaire de Bicêtre, Le Kremlin-Bicêtre, France

1 Correspondence: François Giuliano, MD, PhD, Department of Urology, CHU de Bicêtre, 78 rue du Général Leclerc, 94270 Le Kremlin Bicêtre Cedex, France.

Abstract

Widely distributed throughout the body, cyclic nucleotide phosphodiesterases (PDEs) are functionally heterogeneous enzymes with potential roles in a number of physiological actions. Among these enzymes, PDE type 5 has received particular attention because of the widespread use of the PDE5 inhibitor sildenafil citrate as an oral therapy for erectile dysfunction. Within the corpus cavernosum of the penis, PDE5 catalyzes the enzymatic degradation (inactivation) of cyclic 3',5'-guanosine monophosphate, which is a second messenger and key mediator of vascular and trabecular erectile tissue smooth muscle relaxation. By amplifying the nitric oxide-cyclic nucleotide signalling pathway, PDE5 inhibitors serve as ‘contingent agonists’ of the physiological response to sexual arousal. In experimental models, tadalafil increased the sensitivity of penile resistance arteries and erectile tissues to three stimuli of smooth muscle relaxation, namely electrical field stimulation, sodium nitroprusside, and acetylcholine. In randomized, double-blind, placebo-controlled trials, sildenafil and the investigational agents tadalafil and vardenafil significantly enhanced erectile function in the majority of patients and were well tolerated.

Key Words: Erection • nitric oxide • phosphodiesterase type 5 inhibitors • sildenafil citrate • tadalafil • vardenafil


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J. Appl. Physiol.Home page
I. T. Demchenko, A. Ruehle, B. W. Allen, R. D. Vann, and C. A. Piantadosi
Phosphodiesterase-5 inhibitors oppose hyperoxic vasoconstriction and accelerate seizure development in rats exposed to hyperbaric oxygen
J Appl Physiol, April 1, 2009; 106(4): 1234 - 1242.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.